Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Pruritus - Pipeline Review, H2 2013

Published: Oct-2013 | Format: PDF | Global Markets Direct | Number of pages: 57 | Code: MRS - 986

Global Markets Directs, 'Pruritus Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pruritus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pruritus. Pruritus Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope


A snapshot of the global therapeutic scenario for Pruritus.
A review of the Pruritus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Pruritus pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Pruritus.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pruritus Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Pruritus 8
Pruritus Therapeutics under Development by Companies 10
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Pruritus Therapeutics - Products under Development by Companies 15
Companies Involved in Pruritus Therapeutics Development 16
Johnson & Johnson 16
Shionogi & Co., Ltd. 17
GlaxoSmithKline plc 18
Nippon Shinyaku Co., Ltd. 19
Cara Therapeutics, Inc. 20
ELORAC, Inc. 21
Vanda Pharmaceuticals Inc. 22
Pruritus - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
CT-327 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CR-845 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NS-141 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ZPL-3893787 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VLY-686 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
naloxone hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK-2330672 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PAC-14028 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
JNJ-7777120 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CRG-010 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Next Generation Histamine H4 Antagonists - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Compound-18e - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Drug For Pruritus Ani - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
serlopitant - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Pruritus Therapeutics - Drug Profile Updates 45
Pruritus Therapeutics - Discontinued Products 50
Pruritus Therapeutics - Dormant Products 51
Pruritus - Product Development Milestones 52
Featured News & Press Releases 52
Aug 19, 2013: Velocity Pharmaceutical Development and Tigercat Pharma Announce Submission of IND Application for VPD-737 52
Apr 12, 2013: Elorac's Naloxone Topical Lotion Receives FDA Fast Track Designation For Relief Of Pruritus In Patients With Cutaneous T-cell Lymphoma 52
Dec 22, 2011: Toray, Japan Tobacco And Torii Terminate Joint Development Of Nalfurafine Hydrochloride For Pruritus Associated With Liver Disease In Japan 53
Sep 29, 2011: Trevi Therapeutics Initiates Phase II Study of T111 For Treatment Of Chronic Uremic Pruritus 53
Sep 27, 2011: Trevi Therapeutics Announces Incorporation And Phase II Development Of T111 53
Jul 21, 2011: Merz Aesthetics Announces FDA Approval Of XEOMIN For Temporary Improvement In Appearance Of Moderate To Severe Glabellar Lines In Adult Patients 54
Nov 30, 2010: Elorac Wins Orphan Drug Designation For Naloxone For Treatment Of Pruritus In Cutaneous T-Cell Lymphoma 54
Mar 23, 2009: Torii Pharma To Launch Remitch Capsules 2.5g For Hemodialysis Patients 55
Jan 21, 2009: Toray Announces Manufacturing And Marketing Approval For Remitch Capsules 2.5g In Japan 55
Sep 22, 2005: Aqua Pharmaceuticals Licenses Cordran and Monodox for the United States 55

Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables

Number of Products Under Development for Pruritus, H2 2013 8
Products under Development for Pruritus - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Johnson & Johnson, H2 2013 16
Shionogi & Co., Ltd., H2 2013 17
GlaxoSmithKline plc, H2 2013 18
Nippon Shinyaku Co., Ltd., H2 2013 19
Cara Therapeutics, Inc., H2 2013 20
ELORAC, Inc., H2 2013 21
Vanda Pharmaceuticals Inc., H2 2013 22
Assessment by Monotherapy Products, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 27
Pruritus Therapeutics - Drug Profile Updates 45
Pruritus Therapeutics - Discontinued Products 50
Pruritus Therapeutics - Dormant Products 51 
List of Figures

Number of Products under Development for Pruritus, H2 2013 8
Products under Development for Pruritus - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 23
Assessment by Route of Administration, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Molecule Type, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 27

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing